ÇÒÀιæ
Clinics- Àú³Î ´ÜÇົ
µðÁöÅÐ, ÀΰøÁö´ÉÀÇÇÐ
µ¿¹°º¸°Ç»ç
Çѱ۵µ¼­ ±âÃÊ
Çѱ۵µ¼­ ³»°ú
Çѱ۵µ¼­ ¿Ü°ú
Çѱ۵µ¼­ ¿µ»ó/¾È°ú/Ä¡°ú
Çѱ۵µ¼­ ±âŸ
±âÃÊ »ý¸íÀÇ°úÇÐ
½ÇÇ赿¹°
¼öÀÇ À±¸®/º¹Áö
±â»ýÃæ/»ê°ú/À¯Àü
°øÁߺ¸°Ç/Àü¿°º´ÇÐ
µ¶¼º/¾à¸®,¾àÀü
¸é¿ª/¹Ì»ý¹°ÇÐ
¹ß»ý/ÇغÎ/»ý¸®ÇÐ
Á¶Á÷/º´¸®ÇÐ
¼ö»ýµ¿¹°
Á¶·ù
»ê¾÷/Áß,´ëµ¿¹°
µÅÁö
¸»
¼Ò
°í¾çÀÌ
µ¿¹° º¸Á¤,Çڵ鸵
¼öÀÇ ÀϹÝ/±âŸ Âü°íµµ¼­
¼Òµ¿¹° ³»°ú
¼Òµ¿¹° ¿Ü°ú
ÀçÈ°/½Å°æ, Á¤Çü¿Ü°úÇÐ
³»½Ã°æ, ÀÚ·É/³ë·Éµ¿¹°ÇÐ
ºñ´¢±â/À̺ñÀÎÈÄ°ú
¸¶Ãë,ÅëÁõ/ÀÀ±Þ,¼ö¾×
¼ÒÈ­/¿µ¾ç/ÇǺÎÇÐ
³»ºÐºñ/½Å°æ/ÇൿÇÐ
½ÉÀå,È£Èí±â/Á¾¾çÇÐ
¾È°ú/Ä¡°úÇÐ
¿µ»óÁø´ÜÀÇÇÐ
ÀÓ»óº´¸®(¼¼Æ÷,Ç÷¾×ÇÐ)
´ëüÀÇÇÐ(ħ¼ú,Çãºê)
¾ß»ý/Ư¼öµ¿¹° Exo, Zoo
Á¾º¸Á¸/µ¿¹°º¸È£/¹ýÀÇÇÐ
º´¿ø°æ¿µ/»çÀü/¿ë¾î
BSAVA ½Ã¸®Áî
ÀÚÀ¯°áÁ¦
100ÀÚ ¼­Æò
Áú¹®°ú ´ë´ä
  T: 042-330-0039

  042-361-2500

  HP: 010-8364-0400

  F: 042-367-1017

ÆòÀÏ 10:00 ~ 18:00


À̸ÞÀϹ®ÀÇ
½ÅÇÑ 100-023-144280
±¹¹Î 732801-01-097961
³óÇù 453131-56-197831
Çϳª 660-910336-13307
¿¹±ÝÁÖ: ÀÌ»óµ· okvet
 
 
ºñ¹Ð¹øÈ£ È®ÀÎ ´Ý±â
½ÉÀå,È£Èí±â/Á¾¾çÇÐ > ½ÉÀå/È£Èí±â > Human and Animal Filariases: Landscape, Challenges, and Control

 
Human and Animal Filariases: Landscape, Challenges, and Control
»óÇ°¸í : Human and Animal Filariases: Landscape, Challenges, and Control
Á¦Á¶È¸»ç : Wiley-VCH
¿ø»êÁö : µ¶ÀÏ
Àû¸³±Ý¾× : 8,490¿ø
¼ÒºñÀÚ°¡ : 283,000¿ø
ÆǸŰ¡°Ý : 283,000¿ø
¼ö·® EA
 
¹è¼ÛÁ¶°Ç : (Á¶°Ç)
   
 

Human and Animal Filariases: Landscape, Challenges, and Control



Ronald Kaminsky (Editor), Timothy G. Geary (Editor), Paul M. Selzer (Series Editor)

ISBN: 9783527823420 

October 2022 

656 Pages

Wiley-VCH



DESCRIPTION


Human and Animal Filariases

The rational approach to controlling human and animal diseases caused by nematodes


Filariae are a family of parasitic worms which infect animals and humans, causing severe diseases such as elephantiasis (lymphatic filariasis) and river blindness (onchocerciasis) in humans, as well as heartworm disease (dirofilariasis) in dogs and cats. While the human diseases are rarely fatal, the blindness and disfiguration resulting from these infections constitute a severe burden for the affected individuals and to the healthcare systems in many tropical countries. In 2017, the World Health Organization classified several filariases as neglected tropical diseases and announced a new program seeking to eradicate these infections, which has in turn sparked a new push to develop antifilarial drugs.


Considering the current and future import of this topic, Human and Animal Filariases takes a comprehensive look at infections by filarial parasites in humans and in animals. It begins by reviewing the current state of diagnosis and chemotherapy, before addressing the increasing resistance to available antifilarial drugs. This is followed by strategies and approaches for the discovery of novel drugs and finally by looking at alternative and supplementary approaches to combat the parasites, including vector control and vaccination.


Human and Animal Filariases readers will find:


*A comprehensive approach that integrates current chemotherapy with recent advances in antifilarial drug discovery

*Practical information on assay development, target validation, and required drug product profiles

*Insights from global experts from leading academic institutions as well as from pharma and healthcare companies

Human and Animal Filariases is a unique reference for parasitologists, veterinarians, as well as professionals in the pharmaceutical industry and in public health agencies.



TABLE OF CONTENTS


PART I: Background, Status and Gaps

Filariae as organisms (including life cycles)

Human filariasis - disease and current problems

Canine filariasis (heartworm) - disease and current problems/gaps

diagnosis of human filarial infections

diagnosis of canine filarial infections

Antifilarial chemotherapy: current options (human section)

Antifilarial chemotherapy: current options (veterinary section)

Current products

Current antifilarial drug - mode of action

Drug resistance in canine filarial chemotherapy

Eradication/elimination of human filariae

The economic impact of human filariasis

The economic impact of canine filariasis


PART II: Antifilarial Drug Discovery and Development

Product profiles of new antifilarial drugs -

Discovery and development of new antifilarial drugs (in vitro assays)

Rodent models for the discovery of new antifilarial drugs

Discovery and development of new canine antifilarial drugs (in vivo assays)

Discovery and development of new human antifilarial drugs (in vivo assays)

The drug pipeline, including triple combination therapy, moxidectin, emodepside, TylaMac, auranofin


PART III: Alternative Approaches

Functional genomics of filariae

Vector control approaches: humans

Vector control approaches: canine

Drug targets at the host-parasite interface

Endosymbionts as targets

Vaccines: progress and prospects



ABOUT THE AUTHOR


Ronald Kaminsky, PhD, served as Head of Parasitology Research at Novartis Animal Health from 2006 – 2014 and is currently a consultant for antiparasitic drug discovery in the animal health sector. He teaches as a lecturer at the University of Basel and the Swiss Tropical and Public Health Institute.


Timothy G. Geary, PhD, is Emeritus Professor and past Director of the Institute of Parasitology at McGill University, Professor in the School of Biological Sciences at Queen¡¯s University-Belfast and a consultant to many animal health companies and other organizations.


Paul M. Selzer, PhD, is currently Head of New Mechanisms Parasitology at Boehringer Ingelheim Animal Health. He is also a visiting professor at the Interfaculty Institute of Biochemistry of the University of Tübingen, DE, a teacher at the Department of Life Sciences at the University of Modena & Reggio Emilia, IT, and an honorary professor of the Department of Infection, Immunity, and Inflammation at the University of Glasgow, UK.

 
 
 
 
»óÈ£¸í : OKVET »ç¾÷ÀÚµî·Ï¹øÈ£ : 314-90-93001 314-90-93001 Åë½ÅÆǸž÷½Å°í¹øÈ£ : À¯¼º±¸Ã» Á¦2006-75È£
[ÀÌ¿ë¾à°ü] [°³ÀÎÁ¤º¸ 󸮹æħ] °³ÀÎÁ¤º¸ º¸È£ Ã¥ÀÓÀÚ : ÀÌ»óµ· ´ëÇ¥ : ÀÌ»óµ·
»ç¾÷Àå¼ÒÀçÁö : ´ëÀü±¤¿ª½Ã À¯¼º±¸ Å×Å©³ë3·Î 65, ÇѽŠS-MECA 440È£
Copyright ¨Ï okvet All Rights Reserved. T: 042-330-0039, 042-361-2500, HP: 010-8364-0400, F: 042-367-1017